Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

Background The efficacy of simvastatin in critically ill patients with coronavirus disease 2019
(Covid-19) is unclear. Methods In an ongoing international, multifactorial, adaptive platform …

Acute respiratory distress syndrome (ARDS) is characterised by acute hypoxaemic
respiratory failure with bilateral infiltrates on chest imaging, which is not fully explained by …

The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

Background Recent evidence indicates a potential therapeutic role of fluvoxamine for
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …

Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

The advent of COVID-19 and the persistent threat of infectious diseases such as
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …

Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

Importance A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in
patients with severe and critical COVID-19, but a higher dose may benefit those with more …